南模生物跌4.06% 2021年上市即巅峰募16.5亿元

Core Viewpoint - Nanmo Biology (688265.SH) is currently experiencing a decline in stock price, with a closing price of 47.49 yuan and a drop of 4.06%, indicating a state of being below its initial public offering price [1] Group 1: Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached a peak price of 82.00 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan, as the company initially aimed to raise 400 million yuan for various projects [1] - The total issuance costs amounted to 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [1] Group 3: Planned Use of Funds - The funds raised are intended for several projects, including the establishment of a biological research base, construction of a genetically modified model resource library, development of humanized antibody mouse models, and a drug efficacy platform based on genetically modified animal models, as well as to supplement working capital [1]